Classification of Coronavirus (COVID-19) Treatments and Drugs Based on Mechanism of Action, Efficacy, and Safety

REFERENCES

Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. Immunity, 52(4), 583–589. https://doi.org/10.1016/j.immuni.2020.03.007

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., Ribeiro, A. M., Watson, M., Zaks, T., & Ciaramella, G. (2017). Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Molecular therapy : the journal of the American Society of Gene Therapy, 25(6), 1316–1327. https://doi.org/10.1016/j.ymthe.2017.03.035

Cases in the U.S. (2020, May 7). Retrieved May 30, 2020, from https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html

Carlucci, P., Ahuja, T., Petrilli, C. M., Rajagopalan, H., Jones, S., & Rahimian, J. (2020). Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. https://doi.org/10.1101/2020.05.02.20080036

Casadevall, A., & Pirofski, L.-A. (2020). The convalescent sera option for containing COVID-19. Journal of Clinical Investigation, 130(4), 1545–1548. https://doi.org/10.1172/jci138003

Center for Disease Control. (2020, July 3). COVIDView: A weekly surveillance summary of U.S. COVID-19 activity. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., … Cheng, G. (2004). Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases, 24(1), 44–46. https://doi.org/10.1007/s10096-004-1271-9

Cui, J., Li, F., & Shi, Z. (2018). Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology, 17(3), 181-192. Https://doi.org/10.1038/s41579-018-0118-9

Cunningham, A. (2020, April 8). Can plasma from recovered COVID-19 patients treat the sick? Retrieved May 30, 2020, from https://www.sciencenews.org/article/coronavirus-covid-19-can-plasma-recovered-patients-treat-sick

Devaux, C. A., Rolain, J. M., Colson, P., & Raoult, D. (2020). New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International journal of antimicrobial agents, 55(5), 105938. https://doi.org/10.1016/j.ijantimicag.2020.105938

Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., … Yang, X. (2020, April 28). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Retrieved May 30, 2020, from https://www.pnas.org/content/117/17/9490

Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. Methods in molecular biology (Clifton, N.J.), 1282, 1–23. https://doi.org/10.1007/978-1-4939-2438-7_1

Food and Drug Administration. (2020, May 1). Recommendations for Investigational COVID-19 Convalescent Plasma. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma

Food and Drug Administration. (2020, June 15). Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and

Gandhi, M., Yokoe, D. S., & Havlir, D. V. (2020). Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. New England Journal of Medicine, 382(22), 2158–2160. https://doi.org/10.1056/nejme2009758

Harrison C. (2020). Coronavirus puts drug repurposing on the fast track. Nature biotechnology, 38(4), 379–381. https://doi.org/10.1038/d41587-020-00003-1

Jean, S. S., Lee, P. I., & Hsueh, P. R. (2020). Treatment options for COVID-19: The reality and challenges. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 53(3), 436–443. https://doi.org/10.1016/j.jmii.2020.03.034

Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-I., & Hsueh, P.-R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 55(4), 105933. https://doi.org/10.1016/j.ijantimicag.2020.105933

Kupferschmidt, K. (2020). These drugs don’t target the coronavirus, they target us. Science. https://doi.org/10.1126/science.abc0405

Little P. (2020). Non-steroidal anti-inflammatory drugs and covid-19. BMJ (Clinical research ed.), 368, m1185. https://doi.org/10.1136/bmj.m1185

Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 Vaccines at Pandemic Speed. New England Journal of Medicine, 382(21), 1969–1973. https://doi.org10.1056/nejmp2005630

Magden, J., Kääriäinen, L., & Ahola, T. (2004). Inhibitors of virus replication: Recent developments and prospects. Applied Microbiology and Biotechnology, 66(6), 612-621. https://doi.org/10.1007/s00253-004-1783-3

Management of Patients with Confirmed 2019-nCoV. (2020, May 20). Retrieved May 30, 2020, from https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., … Qian, Z. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-15562-9

Padula W. V. (2020). Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19. Applied health economics and health policy, 18(3), 333–334. https://doi.org/10.1007/s40258-020-00579-4

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., Wagner, W., Granados, A., Greenhouse, J., Walker, M., Willis, E., Yu, J. S., McGee, C. E., Sempowski, G. D., Mui, B. L., Tam, Y. K., … Weissman, D. (2017). Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 543(7644), 248–251. https://doi.org/10.1038/nature21428

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org10.1038/nrd.2017.243

Punt, J., Stranford, S. A., Jones, P. P., Owen, J., & Kuby, J. (2019). Immunology. New York, NY: Macmillan Education.

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., Ciaramella, G., & Diamond, M. S. (2017). Modified mRNA Vaccines Protect against Zika Virus Infection. Cell, 168(6), 1114–1125.e10. https://doi.org/10.1016/j.cell.2017.02.017

Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). Jama. https://doi.org/10.1001/jama.2020.6019

Slomski, A. (2020). No Benefit for Lopinavir–Ritonavir in Severe COVID-19. Jama, 323(20), 1999. https://doi.org/10.1001/jama.2020.6793

Spencer, G. (2020, April 8). A promising COVID-19 treatment gets fast-tracked. Retrieved May 30, 2020, from https://hub.jhu.edu/2020/04/08/arturo-casadevall-blood-sera-profile/

Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H. D., & Rappuoli, R. (2003). SARS--beginning to understand a new virus. Nature reviews. Microbiology, 1(3), 209–218. https://doi.org/10.1038/nrmicro775

Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W. J., Zaki, S., & Murphy, B. (2004). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. Journal of virology, 78(7), 3572–3577. https://doi.org/10.1128/jvi.78.7.3572-3577.2004

Verch, T., Trausch, J. J., & Shank-Retzlaff, M. (2018). Principles of vaccine potency assays. Bioanalysis, 10(3), 163–180. https://doi.org10.4155/bio-2017-0176

Versteeg, L., Almutairi, M. M., Hotez, P. J., & Pollet, J. (2019). Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections. Vaccines, 7(4), 122. https://doi.org/10.3390/vaccines7040122

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., … Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0

Wit, E. D., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., … Feldmann, H. (2020). Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences, 117(12), 6771–6776. https://doi.org/10.1073/pnas.1922083117

Wu, F., Zhao, S., Yu, B., Chen, Y., Wang, W., Song, Z., . . . Zhang, Y. (2020, February 03). A new coronavirus associated with human respiratory disease in China. Retrieved June 18, 2020, from https://www.nature.com/articles/s41586-020-2008-3

Yan, Y., Shin, W. I., Pang, Y. X., Meng, Y., Lai, J., You, C., Zhao, H., Lester, E., Wu, T., & Pang, C. H. (2020). The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. International journal of environmental research and public health, 17(7), 2323. https://doi.org/10.3390/ijerph17072323

Zheng, J. (2020). SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. International Journal of Biological Sciences, 16(10), 1678–1685. https://doi.org/10.7150/ijbs.45053

Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., … Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7

Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016). Coronaviruses — drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327–347. https://doi.org/10.1038/nrd.2015.37